Recent Trends of Infliximab Treatment for Crohn’s Disease
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Crohn’s disease is a chronic inflammatory disorder of the gastrointestinal tract and characterized by relapsing and remitting episodes, with progression over time to complications of stricture, fistulas, or abscesses. The etiology is unknown, although the common opinion is that the disease arises from a disordered immune response to the gut contents in genetically predisposed individuals. Infliximab is a mouse-human chimeric antibody against tumor necrosis factor a, and has proven to be effective in active Crohn’s disease for both induction and maintenance therapy. Despite the growing experience with infliximab in Crohn’s disease, optimal treatment strategies still need to be determined. The purpose of this review is to summarize the current knowledge on the use of infliximab in Crohn’s disease and to discuss the yet-unsolved issues.
Abstract
Crohn’s disease is a chronic inflammatory disorder of the gastrointestinal tract and characterized by relapsing and remitting episodes, with progression over time to complications of stricture, fistulas, or abscesses. The etiology is unknown, although the common opinion is that the disease arises from a disordered immune response to the gut contents in genetically predisposed individuals. Infliximab is a mouse-human chimeric antibody against tumor necrosis factor a, and has proven to be effective in active Crohn’s disease for both induction and maintenance therapy. Despite the growing experience with infliximab in Crohn’s disease, optimal treatment strategies still need to be determined. The purpose of this review is to summarize the current knowledge on the use of infliximab in Crohn’s disease and to discuss the yet-unsolved issues.
참고문헌 (21)
- Cosnes J, "Long-term evolution of disease behavior of Crohn's disease", Inflamm Bowel Dis, 8, pp.244~250 (2002)
- Solberg IC, "Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study", Clin Gastroenterol Hepatol, 5, pp.1430~1438 (2007)
- Munkholm P, "Disease activity courses in a regional cohort of Crohn's disease patients", Scand J Gastroenterol, 30, pp.699~706 (1995)
- Van Assche G, "van der Woude CJ, Sturm A, De Vos M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations", J Crohns Colitis, 4, pp.63~101 (2010)
- Lichtenstein GR, "Management of Crohn's disease in adults", Am J Gastroenterol, 104, pp.465~483 (2009)
- Kozuch PL, "General principles and pharmacology of biologics in inflammatory bowel disease", Gastroenterol Clin North Am, 35, pp.757~773 (2006)
- Hanauer SB, "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial", Lancet, 359, pp.1541~1549 (2002)
- Peyrin-Biroulet L, "Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials", Clin Gastroenterol Hepatol, 6, pp.644~653 (2008)
- Targan SR, "A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease", N Engl J Med, 337, pp.1029~1035 (1997), Crohn's Disease cA2 Study Group
- Hyams JS, "Long-term outcome of maintenance infliximab therapy in children with Crohn's disease", Inflamm Bowel Dis, 15, pp.816~822 (2009)
- "Remicade approved for children with Crohn's disease", FDA Consum, 40, pp.6~ (2006)
- Kugathasan S, "Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease", Am J Gastroenterol, 95, pp.3189~3194 (2000)
- Sands BE, "Infliximab maintenance therapy for fistulizing Crohn's disease", N Engl J Med, 350, pp.876~885 (2004)
- Lemann M, "Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial", Gastroenterology, 130, pp.1054~1061 (2006)
- Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn's disease", N Engl J Med, 362, pp.1383~1395 (2010)
- Hyams J, "Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children", Gastroenterology, 132, pp.863~873 (2007)
- Mackey AC, "Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update", J Pediatr Gastroenterol Nutr, 48, pp.386~388 (2009)
- Siegel CA, "Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis", Clin Gastroenterol Hepatol, 7, pp.874~881 (2009)
- Lichtenstein GR, "Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry", Clin Gastroenterol Hepatol, 4, pp.621~630 (2006)
- Kim MJ, "Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies", Acta Paediatr, 100, pp.451~455 (2011)
- 이지혁, "Efficacy of early treatment with infliximab in pediatric Crohn’s disease", WORLD JOURNAL OF GASTROENTEROLOGY, 16(14), pp.1776~1781, W J G PRESS